Abstract
In this paper, synergistic effects of stereotactic radiotherapy (SRS) combined with karelizumab on the patients with advanced NSCLC have been analyzed through extensive experiments. For this purpose, 100 patients with advanced NSCLC in our hospital from December 2018 to December 2020 were selected and divided into control group and observation group. The control group was treated with SRS, while the observation group was treated with karelizumab at the same time. The data of age, gender, BMI, pathological type, and clinical stage were collected and recorded. After 3 months of treatment, the short-term efficacy of the two groups was evaluated according to RECIST solid tumor efficacy evaluation standard. Fasting venous blood of all patients before and 3 months after treatment was collected. The serum levels of matrix metalloproteinase-9 (MMP-9), cytokeratin 19 fragment (CY211), carcinoembryonic antigen (CEA), and vascular endothelial growth factor (VEGF) were detected by the enzyme-linked immunosorbent assay. The KPS score was used to evaluate the quality of life before and after treatment. The incidence of fatigue, diarrhea, and other adverse reactions were compared between the two groups. The patients were followed up for 3 years, and the survival of all patients was recorded. The total effective rate of the observation group was 50.00% (23/46), which was evidently higher than that (27.78% (15/54)) of the control group (P < 0.05). After treatment, the parameters of CY211, MMP-9, VEGF, and CEA in the two groups were evidently lower than those before treatment, and the parameters of CY211, MMP-9, VEGF, and CEA in the observation group were evidently lower than those in the control group after treatment (P < 0.05). After treatment, KPS parameters of the two groups were evidently higher than those before treatment, and KPS parameters of the observation group were evidently higher than those of the control group after treatment (P < 0.05). The 1-year, 2-year, and 3-year survival rates of the observation group were 95.64% (44/46), 89.13% (41/46), and 80.43% (37/46), respectively, and the 2-year and 3-year survival rates of the observation group were evidently higher than those of the control group (P < 0.05). SRS combined with karelizumab in the treatment of patients with advanced NSCLC has good curative effect, can evidently inhibit the angiogenesis and tumor growth and metastasis, can evidently improve the quality of life of patients, has a good synergistic effect, and can be widely used in clinic.
Highlights
Lung cancer is a malignant lung tumor with a high incidence worldwide, with rapid disease progression, high mortality, and poor prognosis [1]
100 patients with advanced Non-small cell lung cancer (NSCLC) admitted to our hospital from December 2018 to December 2020 were taken as the observation objects, to analyze the synergistic effect of synergistic effects of stereotactic radiotherapy (SRS) combined with carrilizumab in patients with advanced NSCLC
100 patients with advanced NSCLC in our hospital from December 2018 to December 2020 were selected and divided into the control group and observation group. e control group was treated with SRS, while the observation group was treated with karelizumab at the same time. e data of age, gender, BMI, pathological type, and clinical stage were collected and recorded
Summary
Lung cancer is a malignant lung tumor with a high incidence worldwide, with rapid disease progression, high mortality, and poor prognosis [1]. Non-small cell lung cancer (NSCLC) has the highest incidence, accounting for more than 80% of lung cancer [2]. Because the early course of lung cancer is hidden, most patients are already in the middle and late stages when they are diagnosed, and the effect of surgical treatment is poor [3]. With the continuous development of radiological technology in recent years, stereotactic radiotherapy (SRS) has played an important role in the treatment of lung cancer [4]. Nguyen et al [5] found that SRS had achieved good results in the treatment of stage I lung cancer and early multifocal primary lung cancer. The treatment effect of SRS for advanced NSCLC patients is poor, with a high incidence of adverse reactions and poor quality of life of patients. 100 patients with advanced NSCLC admitted to our hospital from December 2018 to December 2020 were taken as the observation objects, to analyze the synergistic effect of SRS combined with carrilizumab in patients with advanced NSCLC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
